Home
Search
Study Topics
Glossary
|
|
|
|
|
Sponsored by: |
National Institute of Allergy and Infectious Diseases (NIAID) |
---|---|
Information provided by: | National Institute of Allergy and Infectious Diseases (NIAID) |
ClinicalTrials.gov Identifier: | NCT00618605 |
Successful control of the HIV epidemic will require a safe and effective vaccine to be developed. A successful vaccine will need to stimulate a widespread immune response. The purpose of this study is to determine the safety of and immune response to an adenovirus serotype HIV vaccine in HIV uninfected adults.
Condition | Intervention | Phase |
---|---|---|
HIV Infections |
Biological: Ad26.ENVA.01 HIV-1 vaccine |
Phase I |
Study Type: | Interventional |
Study Design: | Prevention, Randomized, Double Blind (Subject, Caregiver), Placebo Control, Parallel Assignment, Safety/Efficacy Study |
Official Title: | A Phase 1 Randomized, Double-Blind, Placebo Controlled Dose Escalation Clinical Trial to Evaluate the Safety and Immunogenicity of Recombinant Adenovirus Serotype 26 HIV-1 Vaccine (Ad26.ENVA.01) in Healthy, HIV-1 Uninfected Adults |
Estimated Enrollment: | 48 |
Study Start Date: | June 2008 |
Estimated Study Completion Date: | October 2010 |
Estimated Primary Completion Date: | October 2009 (Final data collection date for primary outcome measure) |
Arms | Assigned Interventions |
---|---|
1: Experimental
3 injections of Ad26.ENVA.01 HIV-1 vaccine or placebo at 1 x 10^9 virus particles (VP) given at Days 0, 28, and 168
|
Biological: Ad26.ENVA.01 HIV-1 vaccine
Recombinant adenovirus serotype 26 HIV-1 vaccine
|
2: Experimental
3 injections of Ad26.ENVA.01 HIV-1 vaccine or placebo at 1 x 10^10 VP given at Days 0, 28, and 168
|
Biological: Ad26.ENVA.01 HIV-1 vaccine
Recombinant adenovirus serotype 26 HIV-1 vaccine
|
3: Experimental
3 injections of Ad26.ENVA.01 HIV-1 vaccine or placebo at 1 x 10^11 VP given at Days 0, 28, and 168
|
Biological: Ad26.ENVA.01 HIV-1 vaccine
Recombinant adenovirus serotype 26 HIV-1 vaccine
|
4: Experimental
2 injections of Ad26.ENVA.01 HIV-1 vaccine or placebo at a dose to be determined by the safety data from Arms 1, 2 and 3 given at Days 0 and 168
|
Biological: Ad26.ENVA.01 HIV-1 vaccine
Recombinant adenovirus serotype 26 HIV-1 vaccine
|
HIV infection continues to spread at pandemic levels throughout the world. Control of this pandemic can only be achieved with the development of a safe and effective preventive HIV vaccine. A vaccine that will prevent HIV infection will elicit a strong immune response from both CD4 and CD8 cells.
Recombinant adenovirus serotype vectors have been shown to elicit just such a response. The purpose of this study is to determine the safety and immunogenicity of the recombinant adenovirus serotype 26 preventive HIV-1 vaccine.
This study will last 12 months. Participants will be randomly assigned to one of four arms that will receive different doses of the vaccine or placebo administered via intermuscular injection. Participants in Arms 1, 2, and 3 will all receive 3 injections. Each injection will contain the same dose of vaccine. Arm 4 will receive 2 injections of a dose of vaccine that will be determined by the safety data from Arms 1, 2, and 3. Participants will be enrolled sequentially, from lowest to highest dose of vaccine, into Arms 1, 2, and 3. Arms will begin enrollment only following review of safety data from the previous group. After the Day 42 safety data from Arms 1, 2, and 3 have been reviewed, the dose for Arm 4 will be determined, and enrollment into that arm will begin.
There will be 10 study visits in this study. Participants in Arms 1, 2, and 3 will receive injections on Days 0, 28, and 168. Participants in Arm 4 will receive injections on Days 0 and 168. Participants will be asked to record their temperature and other side effects in a symptom log for 7 days after each injection. Risk reduction/pregnancy prevention counseling will occur at visits 1 through 9, and physical exams will occur at all visits. At most visits, blood, urine, and oral swab collection will occur. At some visits, HIV testing and pregnancy testing will occur.
Ages Eligible for Study: | 18 Years to 50 Years |
Genders Eligible for Study: | Both |
Accepts Healthy Volunteers: | Yes |
Inclusion Criteria:
Exclusion Criteria:
United States, Massachusetts | |
Brigham and Womens Hospital | Recruiting |
Boston, Massachusetts, United States, 02115 | |
Contact: Lindsey R. Baden, MD 617-732-6801 lbaden@partners.org | |
Principal Investigator: Lindsey R. Baden, MD |
Study Chair: | Lindsey Baden, MD | Brigham and Women's Hospital |
Study Chair: | Dan Barouch, MD, PhD | Beth Israel Deaconess Medical Center |
Study Chair: | Raphael Dolin, MD | Brigham and Women's Hospital |
Responsible Party: | Regulatory Affairs Branch, DAIDS, NIAID ( Mary Ann Luzar, PhD Chief Regulatory Affairs Branch ) |
Study ID Numbers: | Ad26.ENVA.01 |
Study First Received: | February 18, 2008 |
Last Updated: | December 2, 2008 |
ClinicalTrials.gov Identifier: | NCT00618605 History of Changes |
Health Authority: | United States: Food and Drug Administration |
HIV Seronegativity HIV Preventative Vaccine |
Virus Diseases Sexually Transmitted Diseases, Viral HIV Infections Adenoviridae Infections Sexually Transmitted Diseases |
Acquired Immunodeficiency Syndrome Healthy Retroviridae Infections Immunologic Deficiency Syndromes |
Virus Diseases Sexually Transmitted Diseases, Viral RNA Virus Infections Slow Virus Diseases Immune System Diseases HIV Infections |
Sexually Transmitted Diseases Acquired Immunodeficiency Syndrome Lentivirus Infections Infection Retroviridae Infections Immunologic Deficiency Syndromes |